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Riluzoletherapy (HAART), although effective in improving the survival of HIV-1-infected
individuals, has not been able to reconstitute the adaptive immune response. We have described the use of
novel chemical agents to restore T-cell survival/proliferation by inducing cytokine production. Due to its
cationic amphiphilic structure, these molecules appear to enhance immune restoration. In this study, we
investigated the action of Riluzole (2-amino-6-trifuromethoxybenzothiazole) in HIV-1 infection. Riluzole is
able to increase (effective dose from 1 to 1000 nM) the cell-survival of T cells from HIV-1-infected patients
and inhibit spontaneous apoptosis. The immunomodulatory effect of riluzole-sensitized cells was ascribed to
endogenous type I interferon (IFN) derived from monocytes. Riluzole might be used for restoring the cell
survival of immunocompromised patients and eliminating latent infected cells upon HIV-1 reactivation.
© 2009 Elsevier Inc. All rights reserved.IntroductionPatients with HIV-1 infection present a multitude of immuno-
regulatory defects at multiple levels of the immune system (Levy,
2006). Since the use of highly active antiretroviral therapy (HAART),
HIV-related mortality has declined substantially in developed coun-
tries. However, HAART is neither able to eradicate the virus nor has
sufﬁcient immunomodulatory effects to control viral functions
(Jacobson et al., 1997; Lange et al., 2003, Patterson et al., 2008).
Therapeutic efforts to boost antiviral cell-mediated immune immu-
nity are in their infancy. During the past decade, an enormous body of
literature has been accumulated from studies conducted in vitro and in
vivo to examine the participation of various factors in regulating the
enhancementof immune response. Different therapeutic strategies have
been attempted, such as structured treatment interruption (STI),
immunotherapy (interleukin IL-2 and anti-CD3 antibodies) and IL-7, to
try to stimulate HIV-1 out of latency along with antiretroviral
intensiﬁcation therapy (Scripture-Adams et al., 2002; Brooks et al.,
2003;Wangetal., 2005).However, single cytokinesdidnot result inHIV-1
eradication and the combination of IL-7 and IFN-α has been proposed
(Audigé et al., 2005). In addition, many reports indicate that type I IFNniversité Paris Descartes, Centre
ris, France. Fax:+33142863372.
paris5.fr,
l rights reserved.acts as an important stimulator of T cell functions and suggest its use in
AIDS therapy (Belardelli 1995; Vieillard et al., 1997; Lapenta et al., 1999).
We suggested developing a possible alternative strategy using novel
chemical agents to restore immune response (Achour et al.,1998, 2003;
Lu et al., 2001; Achour, 2002). These cationic amphiphilic molecules
enhance T cell proliferation and inhibit cell death. This restored cell
response is associated with the production of cytokines. In the present
study, we have tested the possible immunomodulatory effects of
riluzole (2-amino-6-trifuromethoxybenzothiazole), an anti-glutamate
agent that was thought to affect the course of amyotrophic lateral
sclerosis (Doble, 1999). Riluzole protects neurons by suppression of
glutamate release as well as of ion channels. It is characterized by a
cationic amphiphilic structure with a nitrogen-linked lateral positive
chain (Fig. 1). We show that Riluzole can increase the cell-survival of
HIV-infected T cells in an adherent cell-speciﬁc fashion. In this present
report, immunological and virological properties of Riluzole are
discussed, along with the possibility of its use as part of a combined
antiretroviral-immune rationally based HIV-1 eradication approach.
Results
Riluzole enhances the proliferation of uninfected normal donor T cells
and of HIV-1-infected patients' T cells after anti-CD3/CD28 stimulation
After isolating PBMCs from fresh blood samples, Riluzole was
added at the same time as 2×106 cells were stimulated with anti-CD3/
Fig. 1. Chemical structure of Riluzole (2-amino-6-triﬂuoromethoxy) benzothiazole,
(C8H5F3N2OS, MW 234.20).
Fig. 3. Effects of Riluzole (10 nM) on CD4+, CD8+, naïve (RA+), memory (RO+) and
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culture medium until day 16. An increase in cell survival became
substantial at day 7 and was maintained until the end of culture. In
PBMCs taken from healthy noninfected donors, 2×106 cells at baseline
grew up tomean (±SE) 21 (±7)×106 cells after 14 days of culture in the
absence of Riluzole. Yet the cell number, increased by 1- to 2.5-fold
(50±10×106 cells) with Riluzole (peak response at 10 nM) (Fig. 2A).
PBMCs of the 10 untreated patients increased moderately from 2×106
cells at baseline increased to mean 6 (±1.9)×106 cells at day 14 of
culture in the absence of the drug. In contrast, under Riluzole PBMC
number increased dramatically with a net gain ≥58±17×106 viable
cells (mean≥6-fold, 4.5- to 7.5-fold) at drug concentrations ranging
from 1 to 1000 nM (peak: 10 nM) (Fig. 2B). A slight toxicity was
observed at 10 μM resulting in a bi-shaped curve. In comparison with
the anti-CD3/CD28 stimulation, the number of PHA-stimulated
normal T cell cultures or HIV-1-infected patients in the presence of
Riluzole, increased in the same range (data not shown). Analyses by
ﬂow cytometry demonstrate that the naive (CD45RA+) and memory
(CD45RO+) subsets of both CD4 and CD8 T lymphocytes were equally
expanded by Riluzole (Fig. 3A).
Riluzole increases the proliferation of HIV-1-infected patients T cells after
recall Ag stimulation
We next tested the effects of Riluzole on the proliferation of T cells
fromHIV-infected patients in response to recall Ag, which is known to
be depressed. In response to PPD, the proliferation of T cells from HIV-
infected patients cultured in the presence Riluzole (10 nM), increasedFig. 2. Cell survival (day 14) of PBMC from normal (HIV−, n=5) (A) or HIV-infected
patients (HIV+, n=10) (B) PBMC stimulated with anti-CD3/CD28 Abs and cultured in the
presence of 0.1 nM–10 μM Riluzole. Data were expressed as the mean±SE of the
measurements obtained with 5 normal donors or 10 patient samples.
memory CD4+ and CD8+ T cells (day 14) from 10 HIV-infected patients (A). The mean
levels of cell markers expression over 14 days of culture in the presence or the absence
of Riluzole (10 nM) are shown. Naïve and memory T cells were identiﬁed by multiple
colours staining with antibodies to CD45RA, CD45RO, CD4 and CD8. Data were
expressed as the mean±SE of the measurements. Effect of Riluzole (10 nM) on the
proliferative responses of 10 HIV-infected patients T cells to TCR/CD28 cross-linking (B)
or recall antigen PPD (C). Data were expressed as the mean±SD of the measurements
obtained with 10 patient samples.by 2.5- to 6-fold as shown by the [3H]thymidine uptake T cell index
(Fig. 3C). This increase was similar to that observed in the control
group stimulated with anti-CD3/CD28 Abs (Fig. 3B).
Effect of Riluzole on membrane KI-67 expression
Because Riluzole exerts concentration-dependent proliferative
effects on CD4+ and CD8+ T cells, we measured the fraction of cells
undergoing cycle progression and proliferation in drug-treated cells
from the same patients by using the method of expression of the
nuclear antigen Ki67. No change in Ki67 expression was observed in
early time (days 1–7) with different concentrations of the drug.
Inhibition of Ki67 expression appeared at a later time (day 10) andwas
seen in treated cells with 1–1000 nM Riluzole (peak response at
10 nM). As shown in Fig. 4A, Riluzole could inhibit the Ki-67
expression of PBMC from 10 HIV-infected patients (mean≥45%)
(b0.001). We observed a signiﬁcant decrease in the percentage of
Ki-67+ CD8+ T cells in the Riluzole-treated compared with the
untreated cells (Fig. 4B) (mean≥39%). Difference in Ki-67 expression
Fig. 4. Effects of Riluzole on expression of the nuclear antigen Ki67. Analysis of Ki67
expression in PBMC (A), CD4+ (B) or CD8+ T cells (C) from 10 HIV-1-infected patients
cultured for 14 days in the presence or absence of Riluzole (10 μM–1 nM). Data were
expressed as the mean±SE of the measurements.
Fig. 5. Effects of Riluzole on lymphocyte apoptosis (annexin V binding). Protective
effects of Riluzole against spontaneous apoptosis in cultured puriﬁed populations of T
cells from 10 HIV-1-infected patients. Mean levels of annexin V binding over 14 days of
culture in the presence or absence of Riluzole in PBMC (A), CD4+ (B) or CD8+ (C) T cell
populations. Data were expressed as the mean±SE of the measurements.
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(mean≥42%) (Fig. 4C).
Effect of Riluzole on lymphocyte apoptosis
The comparison of cell apoptosis, as measured by annexin V
binding, in cells treated by Riluzole is shown in Fig. 5. The effects of
Riluzole were evaluated in PBMC from a cohort of HIV-1-infected
subjects (n=10). We calculated the mean of all apoptosis measure-
ments for each patient, and then from those data we determined the
mean value for the 10 patients. The addition of Riluzole induced a
dramatic reduction in the levels of spontaneous apoptosis in cells from
all of the HIV-1-infected patients tested. Riluzole induced an
antiapoptotic effect from the earliest days of culture. At 10 nM, in
treated PBMC a strong inhibition of apoptosis was observed (mean,
63.1±6.7%; pb0.001) (Fig. 5A). As an approach to elucidate whether
Riluzole can protect from apoptosis in both CD4+ and CD8+ T cells
derived from HIV-1-infected individuals, we analyzed separately the
two subpopulations by multiple colour cytoﬂuorimetry within
unfractionated PBMC cultures. The results indicated that Riluzole
treatment reduced the level of annexin V binding in both CD3+CD4+-
and CD3+CD8+-gated cells (mean inhibition, 31.1±2.7% and 53.1±6.7%
respectively; pb0.001) (Figs. 5B and C). This level was signiﬁcantly
reduced after 1 week of treatment with Riluzole in comparison with
untreated cells, and this reduction was maintained until the end of
culture (pb0.001). Reduction of apoptosis consistently was seen at
doses from 1 nM to 1000 nM. A limited antiapoptotic effect of Riluzoleon PBMC from HIV-seronegative individuals was observed. The mean
effect of Riluzole at the 10th day of the culture was signiﬁcantly
different in PBMC fromHIV-1-infected and uninfected subjects (mean,
13.5±5% vs. 1.8±0.9%; pb0.001), considering the peak levels of apo-
ptosis reduction (data not shown).
The immunomodulatory effects of Riluzole are mediated via
adherent cells
The target of Riluzole for the observed increased T cell survival
might be the T cells or monocytes. To address this question, we
puriﬁed T cells from 3 healthy (Fig. 6A) and 3 representative HIV-
infected patient (Fig. 6B). We separated PBMC into a population of
cells that adhered to plastic (the majority of cells are monocytes) and
those that were nonadherent (predominantly B and T cells). These
cells were cultured either in full or separated from adherent cells
(nonadherent cells were enriched for lymphocytes and contained less
than 1% CD14+ monocytes). At day 14, the increased survival was
observed when T cells were cultured in the presence of monocytes but
not in their absence (Figs. 6A and B). To test whether the nature of the
observed increase in T cell survival promoted by monocytes reﬂected
derived soluble factors, we used day 14 supernatants from enriched
adherent cells which contain monocyte cell-derived soluble factors.
Supernatants derived from monocytes cultured in the presence of
Fig. 6. Action of adherent cells on Riluzole effects. Riluzole (10 nM) was assayed on the
survival (day 14) of healthy (HIV−) (A), or HIV-infected individuals (HIV+) (B) cells
stimulated with anti-CD3/CD28 Abs. T cells were cultured in the presence (+ Mo) or the
absence (− Mo) of autologous adherent cells (96% CD14+). Cells without adherent cells
(− Mo) were also cultured either in the presence of 14 day supernatant derived from
untreated monocytes (Spt.U/Mo) or the presence of Riluzole-treated monocytes (Spt.R/
Mo). Each point represents the mean of ﬁve experimental values. Data were expressed
as the mean±SE of the measurements.
Table 2
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the survival of normal (2-fold) (Fig. 6A) and HIV-infected T cells (5-
fold) (Fig. 6B) (pb0.001).
Effect of Riluzole on the production of cytokines in HIV-infected patients
T cells after anti-CD3/CD28 stimulation
The interaction between activated T cells and adherent cells
initiates a series of events leading to the increased or decreased
secretion of cytokines and other unidentiﬁed soluble factors that
shape the fate (survival or depletion) of T cell populations. We
therefore measured a panel of cytokines in the supernatants of T cells
from 10 untreated HIV patients (Table 1). In the presence of RiluzoleTable 1
Effects of Riluzole (10 nM) on the cytokine production of HIV-infected patients' (n=10)
PBMC stimulated with anti-CD3/CD28 Abs in the supernatant of culture1
Cytokine Day 7 of culture Day 14 of culture
Medium Riluzole Medium Riluzole
TNF α (pg/ml) UNDa UND UND UND
IL-1β (pg/ml) 170±25 115±75 105±75 95±85
IL-6 (pg/ml) 5000±1400 3121±855⁎b 2540±155 1850±95⁎
IL-12 (pg/ml) 410±355 485±110 185±155 285±250
IL-15 (pg/ml) 3.2±1.9 12.8±2.7⁎ UND 26.2±7.5⁎
IL-18 (pg/ml) 66.6±20.8 74.6±17.8 UND UND
IFN activity (IU/ml)c UND 96±25⁎ UND 64±12⁎
IFN activity+anti-Type I IFNeIFNd UND UND UND UND
1Data were expressed as the mean±SE of the measurements.
a UND, Undetectable (i.e., below the detection threshold of commercial ELISA kits).
b ⁎pb0.01 as compared with culture medium alone.
c IFN activity was determined by the inhibition of the cytopathic effect of vesicular
stomatitis virus (see Materials and methods).
d The type I IFN activity was determined using neutralizing anti type 1(α/β) IFN
antibodies 2×102 neutralizing units).(10 nM), the concentrations of IL-1β, TNF-α, IL-10, IL-12 and IL-18
were not affected. The concentration of IL-6 started to decline
signiﬁcantly at day 7 (50% less) and (30%-less) at day 14 of culture.
In contrast, IL-15 and IFN activity were signiﬁcantly increased by
Riluzole (pb0.001). When anti-Type I IFNs (α/β) were used the IFN
activity was totally abrogated (Table 1).
The observed increased T cell survival might be associated with
IFN induced by Riluzole. To answer this question, we cultured cells
from 3 representative HIV-1-infected patients after activation with
anti-CD3/anti-CD28 Abs. These cells were cultured either alone or
treated with Riluzole. In addition, these conditioned cells were
cultured in the presence of neutralizing antibodies towards IFN-α,
IFN-β, or IFN-α plus IFN-β (Table 2). In Riluzole-treated cells and
conditioned with IFN antibodies (anti-IFN-α or anti-IFN-β) a partial
increase in T cell survival was observed (3.8 fold and 1.8 fold). This
cell survival was totally inhibited when anti-IFN-α and anti-IFN-β
antibodies were used together. Moreover, the inhibition of apoptosis
in Riluzole-treated cells was abrogated in the presence either of anti-
IFN-α or anti-IFN-β alone. Exogenous leukocyte type I IFN (contain-
ing α and β IFN) is not effective at doses ranging from 30 to 200 IU
(data not shown). When neutralizing antibodies against IL-15 was
used in drug-treated cells no speciﬁc effect was observed. We also
directly tested the role of IL-2 on the effect of Riluzole. When
recombinant human IL-2 was withdrawn from the standard
lymphocyte culture medium, we observe a signiﬁcant reduction in
T cell apoptosis. Nevertheless, the increased T cell survival promoted
by Riluzole, even positive, was signiﬁcantly lower (5-fold less at the
14th day of the culture) dependant on the presence of exogenous IL-2
(Table 2, pb0.001).
Effect of Riluzole (10 nM on the supernatant virion RNA of 10
HIV-infected patients' T cells
We further determined whether Riluzole could prevent PBMC
from viral production. T cells from 10 infected patients were
expanded by anti-CD3/anti-CD28 stimulation in the presence or
the absence of the drug (Fig. 7). Therefore the HIV-1 production was
examined by measuring supernatant viral RNA. At day 3, 6, 9 and 15
of culture Riluzole increased by 1 log10 (pb0.001) the HIV RNA in
the supernatant of the same cultures in comparison with untreated
cells (Fig. 7). However at day 12 no difference was observed. It is
worthy to indicate that in treated cells a strong correlation was
observed between viral load and cell expansion (R: 0.70) (data not
shown).Effects of anti-Type I IFN antibodies or IL-2 on cell survival and apoptosis in cells treated
with Riluzole
Number of viable cells % of apoptotic T cells
(−) Riluzole (+) Riluzole (−) Riluzole (+) Riluzole
C.Ma 3.9±3 35±6⁎ 45±10 12±6⁎
C.M (−) IL-2b 1.8±0.7 3.5±0.4⁎ 65±18 25±8⁎
C.M (+) anti-IL-15c 1.6±0.5 37±3⁎ 55±7 15±0.7⁎
C.M (+) Ctr. IgGd 4±2 38±6⁎ 48±9 15±3⁎
C.M (+) Anti-IFNαe 3.9±3 15±8⁎ 38±6 33±7
C.M (+) Anti-IFNβf 4.2±2 8.5±3⁎ 37±8 39±6
C.M (+) Anti-IFNα+β 4.8±3 5.2±2 39±4 36±7
2×106 cells were activated at day 0 (see Materials and methods) and measures
performed at day 14 of the culture.
Each value represents the mean±s.e.m of triplicate determinations of 3 series of cells.
⁎pb0.001 vs control (−Riluzole).
a Complete medium (C.M) supplemented with recombinant IL-2.
b Cells were cultured in the absence of IL-2.
c Goat anti human IL-15 was used was used at 2 μg/ml (R&D).
d Sheep IgG were used as controls.
e Sheep polyclonal antibodies against IFN-α (2×102 neutralizing units).
f Sheep polyclonal antibodies against IFN-β (2×102 neutralizing units).
Fig. 7. Effects of Riluzole (10 nM) on the supernatant virion RNA of 10 HIV-infected
patients' T cells stimulated with anti-CD3/CD28 Abs and cultured from day 3 to day 15.
Viral production was determined by measuring cell-free HIV RNA (equivalent copies/
ml) by a multiple primer-induced overlapping ampliﬁcation assay with a detection
threshold of 10 equivalent copies/ml (A). Data were expressed as the mean±SE of the
measurements obtained with 10 patient samples.
Fig. 8. Effect of Riluzole on gene expression in PBMC. Fresh PBMC from 3 healthy donors
were treated for 4 h by Riluzole (10 nM) before RNA extraction and analysis by real time
RT-PCR. Results are expressed in % mRNA relative to control (not treated cells) taken as
100% of each gene. Each value represents the mean±S.E of triplicate determinations of 3
different series of experiments. ⁎⁎⁎pb0.001 vs. control.
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To explore the mechanism underlying the immune-modulatory
activity promoted by Riluzole, we evaluated the expression of
cytokines and innate immunity genes in PBMC from 3 healthy
individuals. We used quantitative RT-PCR experiments to study IL-8,
IL-10, Il-12/IL-23, IL-15, IL-18, TLR-2, TLR-3, TLR-7, TLR-9, IFN-α and
IFN-β gene expression in PBMC after 4 hour-treatment by the drug
(10 nM). After ampliﬁcation, the amount of cytokines mRNAs in the
Riluzole-stimulated PBMC versus un-stimulated was increased 8.5-
fold with IFN-α, 5-fold with IFN-β, 2-fold with IL-15, 2.5-fold with
TLR-3 and 1.4-fold with TLR-7 (Fig. 8) (pb0.001). Moreover, after 24 h
of culture the IFN activity was increased when compared to untreated
PBMC (S.E, 90 IU±40 vs. 7±3; pb0.001).
Discussion
The major obstacle to HIV-1 eradication is the establishment of a
latent infection which dampers the cure of AIDS. However, HAART is
neither able to eradicate the virus nor has sufﬁcient immunomodu-
latory effects to control viral-infection. In HIV-1-infected individuals,
phenotypic and functional immunologic abnormalities may persist
even in patients with sustained suppression of viremia for several
years (Smith, 2001). Since functional immune reconstitution is limited
after HAART, the use of adjunctive immune-modulation remains an
urgent need for HIV therapy. Cytokines such as IL-2 and IL-7, and IL-15
have been proposed to improve immune reconstitution (Imani and
Gotch, 2002; Nunnari and Pomerantz, 2005; Ahmad et al., 2005;
Vassena et al., 2007; Michaëlsson et al., 2008).
On the other hand, we proposed a new approach aiming at
enhancing immune restoration by using chemical agents. The
observation that improvement by Riluzole of the survival of T cells
from HIV-infected patients suggests its potential application as an
adjuvant in HIV therapy. Although Riluzole induced cell survival in
PBMC from all of the patients analyzed, we consistently observed a
constant association with the antiapoptotic effect. Riluzole exerts
protective effects against the spontaneous apoptosis of both CD4+ and
CD8+ T cells derived from HIV-1-infected individuals. The antiapopto-
tic effect was already evident at day 3 andmaintained at the end of the
culture. The decreased expression of the cell cycle marker Ki-67 and of
the percent of apoptotic cells after 14 days of culture in the presence of
Riluzole might be interpreted as a consequence of the re-entry of a
majority of T cells into the G0 cell cycle phase.The improvement by Riluzole of the survival/proliferation of T cells
from HIV-infected patients correlates with a signiﬁcant decreased
production of IL-1β and IL-6 and a slight production of IL-15.
Moreover, this improvement is dependent of exogenous IL-2. An
unexpected ﬁnding emerging from our study is that the enhancement
of cell-survival as well as the reduction of apoptosis mediated by
Riluzole in cultures was correlated with the synthesis of type I IFN
(α,β). Only endogenous induced type I IFN has the beneﬁcial effect
whereas exogenous IFN is not effective. The complete mechanism
whereby Riluzole modulates the IFN activity has to be elucidated.
However, Riluzole dependently of its action on cell survival/apoptosis
might improve the IFN system, including various IFN-induced gene
products. IFN-mediated signaling and transcriptional activation of
cellular gene expression are best described in the context of JAK-STAT
pathway proteins. Moreover, different members of the JAK and STAT
families have distinct functions in cytokine signaling and additional
signaling pathways are also activated by IFN (Andrea and Pitha, 2007).
Analysis of the transcription signature of IFN-induced genes shows
that IFN induction results in a major upregulation of cellular gene
expression. We do not exclude that other IFN-stimulated proteins
derived frommonocytes might enhance the effect of endogenous IFN.
IFN can cooperate with numerous T cell mitogens, including IL-2 and
unknown factors, and can contribute to the cell survival restoration.
Whether the drug activity and its associated response are due to the
activation of STAT4-dependent pathways or other proteins remains to
be determined (Curtsinger et al., 2005). Furthermore, our observations
suggest that Riluzole by restoring cell survival and inhibiting
apoptosis might facilitate the expression of IFN receptors necessary
to the immune-modulatory effect. Ongoing work is aimed to study the
effect of Riluzole on the expression of the type1 IFN receptor.
Evidence has already been developed which demonstrates that
AIDS patients are not capable of producing IFNs. In AIDS, patients
manifest an abnormal acid-labile circulating IFN-α and are not
capable of producing interferon following in-vitro viral induction
(Lopez et al., 1983; Hersh et al., 1985). This impairment of IFN-α
production did not positively correlate with the serum levels of this
cytokine that increased at later stages of the disease (Rossol et al.,
1989). Paradoxically, the appearance of IFN activity in sera of HIV-
infected patients is associated with disease progression suggesting
that other cellular factors might regulate the antiretroviral effects of
IFN (Francis et al., 1992). This responsiveness, probably due to
inappropriate activation, may be related to the state of anergy
observed in AIDS. It was also reported that cellular responsiveness
to exogenous IFN is altered in HIV infection (Rodriguez et al., 2006;
Jiang et al., 2005) and only higher doses of IFNα provided protection
from apoptosis in cells from AIDS patients (Rodriguez et al., 2006). In
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effective. When antibodies neutralized endogenous IFN no beneﬁcial
effect is observed. Thus, our results appear to be consistent with
results by others showing that even very low of IFN produced by
genetically modiﬁed human lymphocytes can enhance T cell reactivity
(Vieillard et al., 1997).
In treated cells, Riluzole promotes an increase of viral RNA. Our
data clearly indicate that these high levels of viremia do not
necessarily lead to cell survival dysfunction. Ongoing work is aimed
at determining whether the high level of viral RNA reﬂected the
presence of either infectious or defective virus. Our approach does not
target latently HIV-1 infected cells directly. Nevertheless, this mean is
aimed at enhancing cell survival to more rapidly and effectively
eliminate latent cells upon reactivation of HIV-1 expression. Establish-
ment of latency is driven by selection of cells that resist viral
replication. Then, by maintaining the cell survival associated with a
high viral expression an elimination of latent virus might be possible.
Further studies are also necessary to study latent viral burden by
limiting dilution micro co-culture assay.
The mechanisms of action of Riluzole include inhibition of
glutamate release, inactivation of voltage-dependent Na+ channels,
and interference with G protein-dependent signaling (Van Den Bosch
et al., 2006). Riluzole which blocks the release of glutamate and
aspartate from nerve terminals prevents the neuronal degeneration
induced by gp120 in cortical cell cultures (Sindou et al., 1994). These
results suggested that toxic factors produced by activated macro-
phages might increase glutamate release, and that this may be
prevented by Riluzole. Others reported that treatment of human
melanoma cells with Riluzole, suppresses glutamate release and cell
growth (Namkoong et al., 2007). In this study treatments with only
high doses of Riluzole (10–50 μM) inhibited growth of human
melanoma cells and induced cell cycle arrest. Comparatively in our
report, when Riluzole is used at lower concentrations (0.001–1 μM) an
immune-momodulatory effect is observed. Riluzole as a cationic
amphiphilic molecule has the property to act at the mRNA level of
cytokines as demonstrated for other drugs of this category (Achour et
al., 1998; Lu et al., 2001; Achour, 2002; Achour et al., 2003. These
results prompted us to validate the new action of Riluzole in human
immune cells.
Type I IFN are induced by viral infections and also produced
constitutively at low levels in haematopoietic tissues and have been
imputable various roles, particularly immune system (Sen, 2001;
Biron, 2001). These functions include effects on the proliferation,
survival and differentiation of T lymphocytes, the maturation of B-
lymphocytes, and the proliferation and differentiation of dendritic
cells (Curtsinger et al., 2005). IFN α/β can cooperate with numerous
T-cell mitogens, including IL-2, IL-4, IL-7, and IL-12 and can
contribute to the restoration of the immune system (Nunnari et al.,
2005) and are important factors in innate immunity, through their
enhancement in T cell stimulation (Belardelli, 1995; Curtsinger et al.,
2005). In PBMC Riluzole can induce the mRNA expression of TLR3
and TLR7, which were implicated in innate immunity. Single strand
(ss) RNA is recognized by TLR7. TLR3 can be activated by dsRNA
suggesting that viral dsRNA, either genomic or replication inter-
mediate, is critical for the antiviral response (Andrea and Pitha,
2007).
Many experimental reports have indicated that endogenous type I
IFN either present constitutively or possibly induced play an
important role in host defence (Gresser and Belardelli, 2002). In
patients, the lack of response to IFN therapy is partly due to inhibitory
activity in the ﬂuids. To overcome IFN resistance, increasing
endogenous IFN production able to reverse the inhibitory effects has
been suggested (Chadha et al., 2004). Nevertheless, the striking
importance of the endogenous type I IFN produced constitutively or
induced by chemical products could open a new way to revaluate IFN
in HIV therapy. The development of new strategies that are based oninduction of endogenous IFN in addition to chemotherapeutic
suppression of virus replication may be envisioned.
Materials and methods
Subjects
Blood samples were obtained from whole blood of 5 healthy
donors or 10 untreated HIV-1-infected patients who had 200–400
CD4 cells/μl, 37–64 CD4+ naïve cells/μl, 166–316 CD4+ memory cells/μl
and ≥104 plasmaHIV RNA equivalent copies/ml (Lu et al., 2001, Achour
et al., 2003). The study was performed in accordancewith local ethical
committee standards and all patients provided informed consent as
previously reported (Lu et al., 2001).
Cells and culture conditions
PBMC were isolated from fresh whole heparin-treated blood of
healthy donors or HIV-1-infected patients by Ficoll-Hypaque (Eurobio,
Les Ulis, France) density gradient centrifugation. Cells were then
seeded at 2×106/well in 24-well plates (Nunc, Roskilde, Denmark) and
were stimulated with or 0.5 μg/ml anti-CD3 mAbs (Becton Dickinson
France, Le Pont-de-Claix, France) plus 100 ng/ml anti-CD28 mAbs (BD
PharMingen, Los Angeles, CA) in the absence or the presence of
Riluzole (PT, Sigma) at indicated drug concentrations. After overnight
stimulation with anti-CD3/CD28 Abs, cells were washed and resus-
pended at 106/ml in complete medium containing the same
concentrations of the drug plus 20 IU/ml recombinant human IL-2
(Boehringer Mannheim, Mannheim, Germany) for a 20-day period
culture. Cultures were maintained at 37 °C in humidiﬁed air at 5% CO2.
Culture mediums were adjusted every 2–3 days keeping the cultures
at a viable cell density 1×106/ml with complete medium in the
absence or the presence of the drug. At each time point, viable cell
counts were determined by trypan blue exclusion and supernatants
were harvested for storage at −20 °C. To obtain nonadherent cells,
PBMC were subjected to plate adherence for 12 h. Adherent cells
contained more than 93% CD14+ monocytes and were determined on
their expressions of CD86+, CD32+, CD14+, CD11c+, CD83−, CD4−, and
CD8−. Nonadherent cells were enriched for lymphocytes and con-
tained less than 1% CD14+ monocytes and were determined to be 95%
CD3+ T cells assessed by direct immunoﬂuorescence ﬂow cytometry.
Proliferation assay
PBMC were freshly isolated from 10 untreated patients. Cells were
resuspended at a cell concentration of 5×105/ml in complete medium
and seeded in quadruplicate in 96-well round-bottom microtiter
plates (Nunc) containing 105 PBMC/well. Cells were stimulated with
3000 U/ml puriﬁed protein derivative (PPD) of tuberculin (Aventis
Pasteur, Lyon, France) in the absence or the presence of Riluzole at
indicated concentrations. Microtiter plates were placed in a cell
incubator in a humidiﬁed atmosphere containing 5% CO2 for 96 h. Cells
were pulsed with 1 μCi/well [3H]thymidine (Amersham, Aylesbury,
U.K.) for the ﬁnal 16 h. Cells were harvested on glass ﬁber ﬁlters by an
automated multisample harvester; ﬁlters were then put in tubes with
liquid scintillation ﬂuid and counted on a beta scintillation counter.
Apoptosis assay
Apoptotic cells were measured by propidium iodide and FITC-
labelled annexin V, a phospholipid-binding protein that preferentially
binds to phosphatidylserine exposed at the cell surface in the early
phase of apoptosis, using a commercially available kit (Immunotech,
Marseille, France). Cells that were negative for propidium iodide and
positive for annexin V were identiﬁed as apoptotic cells, whereas
those positive for both propidium iodide and annexin V were
166 A. Achour et al. / Virology 386 (2009) 160–167considered prenecrotic cells. The cells then were analyzed by ﬂow
cytometry.
Flow cytometry
CD4+, CD8+ T cell counts as well as KI-67 positive cells were
assessed by ﬂow cytometry analysis (FACScan, BD Biosciences, San
Jose, CA). The mAbs to the following T cell surface markers was used:
CD3-PerCP, CD4-FITC, CD8-PE, CD4-PerCP, CD8-PerCP, Ki-67-PE,
CD45RO-PE, CD45RA-PE (Becton Dickinson France) and CD86-FITC,
CD32-FITC, CD11c-FITC, CD83-PE (BD PharMingen). In each analysis
10,000 events were analyzed.
Intracellular staining
The cells were ﬁxed in a ﬁnal concentration of 1% formaldehyde at
4 °C overnight. Subsequently theywerewashed in PBS and then in PBS
containing 2% FCS and 0.1% saponin (Sigma, St. Louis, MO). PE-
conjugated anti-Ki-67 (Pharmingen) in 30 μl of PBS/saponin was used
to stain each sample for 60 min (30 min at 4 °C followed by 30 min at
room temperature).
Cytokine detection
Cell-free supernatants collected at days 7 and 14 of culture were
assayed for TNF-α, IL-1β, IL-6, IL-12, IL-15, IL-18 using commercial
ELISA kits (Quantikine; R&D Systems). The sensitivity of the assay for
each cytokine was 4.4 pg/ml for TNF-α, 1 pg/ml for IL-1β, 0.7 pg/ml for
IL-6, 5 pg/ml for IL-12, 1 pg/ml for IL-15, and 15 pg/ml for IL-18
respectively.
Viral quantitation assay
Viral production was determined by measuring cell-free HIV RNA
by a multiple primer-induced overlapping ampliﬁcation assay with a
detection threshold of 10 equivalent copies/ml (Lu et al., 1999, Achour
et al., 2003).
Interferon assay
IFN antiviral activity was determined by the inhibition of the
cytopathic effect of vesicular stomatitis virus (VSV, Indiana strain) (1
pfu per cell) on human Wish cells. IFN titers, given in international
units (IU) are expressed in relation to the Reference Human Interferon
Alpha code GA-902-530 from the National Institut of Health
(Bethesda, Md., U.S.A). 1 IU/ml refers to an interferon concentration
that results in 50% inhibition of viral yield compared to the standard.
Natural human type I IFN from leukocytes was originated from our
laboratory and its speciﬁc activity was 2.5 106 IU/mg of protein (Jiang
et al., 1988).
Sheep polyclonal antibodies against IFN-α or and IFN-β (R&D, PBL
Biomedical Laboratories, USA) were used in neutralization experi-
ments. 100 μl cell free supernatant was incubated with 100 μl of the
neutralizing antibodies (102 U IFN-β or/and 102 U IFN-α) for 2 h at
37 °C. Each assay was performed in triplicates. For neutralizing
studies in cultures, cells were incubated in complete medium sup-
plemented with anti-IFN antibodies (200 neutralizing units of IFN-α,
β, or α/β). Thereafter the antibodies were added at each renewal of
the cultures.
Real-time RT-PCR
RNA extraction was carried out by RNeasy Mini Kit (Qiagene,
Courtaboeuf). RNA was quantiﬁed using the Nanodrop spectro-
photometer (Nanodrop Technologies, Wilmington, DE), and its quality
was assessed by gel electrophoresis. The ﬁrst-strand cDNA wassynthesized using High Capacity cDNA Archive (Applied Biosystems,
Courtaboeuf, France). Quantitative RT-PCR measurements using SYBR
Green (QIAGEN) were performed on an ABI Prism 7900 Sequence
Detector system (Applied Biosystems). The relative mRNA levels of
cytokines were estimated using glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) as the reference gene (Khazen et al., 2007).
GAPDH (5′-AACAGCCTCAAGATCAGCAA-3′)–(5′-CAGTCTGGGTGG-
CAGTGAT-3′), TLR-2 (5′-CTCTCGGTGTCGGAATGTC-3′)–(5′-AGGGGG-
GATTGAAGTTCTC-3′), TLR-3 (5′-ACGAGACCCATACCAACATCC-3′)–(5′-
TTCCCAGACCCAATCCTTATC-3′), TLR-7 (5′-GACCTCAGCCACAACCAAC-
3′)–(5′-TAACCCACCAGACAAACCAC-3′), TLR-9 (5′-CTACAACCG-
CATCGTCAAAC-3′)–(5′CATTCAGCCAGGAGAGAGAAC-3′), IFN-α (5′-
ACTTTGGATTTCCCCAGGA-3′)–(5′-CAGGCACAAGGGCTGTATT-3′), IFN-
β (5′-ATCTAGCACTGGCTGGAATGAG-3′) (5′TTCGGAGGTAACCTGT-
AAGTCTG-3′), IL10 (5′GCTGGAGGACTTTAAGGGTTACCT3′)–(5′
CTTGATGTCTGGGTCTTGGTTCT-3′), IL-12/IL-23 P40 (5′-TGGAGTGC-
CAGGAGGACAGT-3′)–(5′-TCTTGGGTGGGTCAGGTTTG-3′), IL-15 (5′-
CCATCCAGTGCTACTTGTGTTTAC3′)–(5′CCAGTTGGCTTCTGTTTTA-
GGAA-3′), IL-18 (5′-GACGCATGCCCTCAATCC-3′)–(5′-CTAGAGCG-
CAATGGTGCAATC-3′).
Each sample was quantiﬁed against its GAPDH transcript contents,
and then normalized with the control group. The results were
repeated three times and presented as fold of increase±SE.
Statistical analysis
Paired data between different in vitro treatments were compared
by the t test.
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